Adult Tic Disorders Registry (RegisTICs)
August 27, 2025 updated by: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to develop the adult tic disorders registry in order to characterize the relationship between tic severity and tic-related impairment in women compared to men with tic disorders.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
450
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emmanuel Flamand-Roze, MD, PhD
- Phone Number: +33 1 42 16 06 45
- Email: emmanuel.flamand-roze@aphp.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU Clermont-Ferrand
-
Contact:
- Isabelle JALENQUES, MD
- Phone Number: 0033 4 73 75 21 05
- Email: ijalenques@chu-clermontferrand.fr
-
Principal Investigator:
- Isabelle JALENQUES, MD
-
Limoges, France, 87042
- Recruiting
- CHU Limoges
-
Principal Investigator:
- Jean-Luc HOUETO, MD
-
Contact:
- Jean-Luc HOUETO, MD
- Phone Number: 0033 5 55 05 65 60
- Email: jean-luc.houeto@chu-limoges.fr
-
Marseille, France, 13003
- Recruiting
- CHU Marseille
-
Contact:
- Tatiana WITJAS, MD
- Phone Number: 0033 4 91 38 43 33
- Email: Tatiana.WITJAS@ap-hm.fr
-
Principal Investigator:
- Tatiana WITJAS, MD
-
Paris, France, 75013
- Recruiting
- Service de Neurologie, GH Pitié Salpêtrière
-
Contact:
- Emmanuel FLAMAND-ROZE, MD
- Phone Number: +33 01 42 16 24 81
- Email: emmanuel.flamand-roze@aphp.fr
-
Poitiers, France, 86000
- Recruiting
- Chu Poitiers
-
Contact:
- Solène ANSQUER, MD
- Phone Number: 0033 5 49 44 44 44
- Email: solene.ansquer@chu-poitiers.fr
-
Principal Investigator:
- Solène ANSQUER, MD
-
Saint-Herblain, France, 44800
- Recruiting
- CHU Nantes
-
Contact:
- Philippe DAMIER, MD
- Phone Number: 0033 2 40 16 52 12
- Email: philippe.damier@chu-nantes.fr
-
Principal Investigator:
- Philippe DAMIER, MD
-
Strasbourg, France, 67200
- Recruiting
- CHU Strasbourg
-
Principal Investigator:
- Mathieu Anheim, MD
-
Contact:
- Mathieu ANHEIM, MD
- Phone Number: 0033 3 88 12 85 85
- Email: mathieu.anheim@chru-strasbourg.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patient with tics disorders
Description
Inclusion criteria :
- Age >18 years
- Patients with Tic disorders
- Given the non-opposition
Non Inclusion criteria
- No affiliation to a French health social insurance
- Significant congenital disorders that may affect understanding of assessments
- Patients under guardianship or curatorship
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Quality of life questionnaires
|
The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between Quality of Life and TICs severity
Time Frame: 6 months
|
Severity of the tics measurement (YGTSS Impairment Score) and the quality of life (TS-QOL) between men and women with tic disorders, while controlling for the YGTSS Total Tic Score
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in TICs
Time Frame: 6 months
|
Change in tic inventories/tic migrations with the YGTSS tic inventories
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2021
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
September 22, 2021
First Submitted That Met QC Criteria
October 11, 2021
First Posted (Actual)
October 25, 2021
Study Record Updates
Last Update Posted (Estimated)
September 4, 2025
Last Update Submitted That Met QC Criteria
August 27, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP210801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.